Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore! Learn More →

Recruiting NCT06551584

Trial for Patients w/ Advanced Hematologic Malignancies Undergoing Allogeneic HCT

Conditions: Acute Myeloid Leukemia, Acute Lymphoid Leukemia, Mixed Phenotype Acute Leukemia, Myelodysplastic Syndromes

Sex: All

Ages: 18 Years – 70 Years

Healthy volunteers: No

Phase: PHASE1

Enrollment: 24

Sponsor: Stanford University

Location: Stanford University Palo Alto California

Summary

The study goal is to characterize the safety of the combination of Orca-T with dual agent GVHD prophylaxis.

Eligibility Criteria

Inclusion Criteria: 1. Eligible diseases: * Acute myeloid, lymphoid or mixed phenotype leukemia in complete remission (CR) or CR with incomplete hematologic recovery (CRi) as defined in Section 6.1.3; with or without the presence of known minimal residual disease, or * Myelodysplasic syndrome (MDS) myelodysplastic syndromes eligible for alloHSCT and/or treatment-related MDS \

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT06551584). StuddyBuddy aggregates publicly available trial information.